PT-141 (Bremelanotide): The FDA-Approved Peptide for Sexual Health

What Is PT-141 (Bremelanotide)?

PT-141, known generically as bremelanotide, is a synthetic cyclic heptapeptide — a small protein ring made up of seven amino acids. It is a metabolite of Melanotan II, derived when that compound is metabolized in the body. The story of PT-141 begins not in a sexual health clinic, but in a skin pigmentation laboratory in Tucson, Arizona.

Bremelanotide activates melanocortin receptors, particularly MC3R and MC4R, which are located predominantly in the hypothalamus and other areas of the central nervous system. This activation initiates signaling pathways that influence sexual desire and arousal — not by acting on the genitals, but by acting on the brain itself.

In June 2019, the U.S. Food and Drug Administration approved bremelanotide under the brand name Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. It was the second ever FDA approval for HSDD, and the first that works centrally via the nervous system rather than through hormonal or vascular pathways.

From Melanotan II to Vyleesi: A Brief History

The discovery of PT-141's sexual effects was, by most accounts, an accident.

In the 1980s, researchers at the University of Arizona — led by Victor Hruby and Mac Hadley — were investigating whether synthetic analogs of alpha-melanocyte-stimulating hormone (α-MSH) could be used to stimulate skin tanning without UV exposure. The hypothesis was that if you could trigger melanin production safely, you might reduce skin cancer rates by giving people a "pharmaceutical sunscreen."

This work produced two compounds: Melanotan I (afamelanotide) and Melanotan II (MT-II). Melanotan II was a more potent, cyclic version that bound not only to the MC1R receptor in melanocytes but also to MC3R and MC4R in the brain. And in early self-experiments with MT-II, researchers observed something unexpected: spontaneous, prolonged erections.

The erections weren't the goal. They were a side effect — an entirely unplanned pharmacological finding. But they were pronounced enough that researchers recognized them as a signal worth following. If MT-II could produce sexual arousal in humans via the central nervous system, that pathway might be therapeutically relevant, particularly for people whose sexual dysfunction stemmed from desire, not physical response.

Further research on Melanotan II's aphrodisiac properties eventually produced a stripped-down analog — bremelanotide (PT-141) — that retained the CNS sexual function activity while reducing some of the side effects, particularly the hypertension that Melanotan II produced. A pharmaceutical company (Palatin Technologies) licensed the compound and pursued clinical development specifically for sexual dysfunction.

For more on the Melanotan family and how it relates to PT-141's origins, see our article Melanotan Peptides: What to Know About Melanotan I and II.

The Melanocortin System Explained

To understand how PT-141 works, you need a working model of the melanocortin system — one of the body's most versatile signaling networks.

The melanocortin system consists of a family of five G-protein-coupled receptors (MC1R through MC5R), each expressed in different tissues and governing different functions:

• MC1R — Expressed on melanocytes in skin; governs melanin production and skin pigmentation; also expressed on immune cells
• MC2R — Expressed in the adrenal cortex; binds ACTH (adrenocorticotropic hormone); regulates cortisol production
• MC3R — Expressed in the hypothalamus and limbic system; involved in energy balance, reproductive behavior, and autonomic function
• MC4R — Widely expressed in the central nervous system, particularly the hypothalamus; plays a major role in energy homeostasis, sexual function, and autonomic regulation
• MC5R — Expressed in exocrine glands; regulates secretory function

The endogenous ligands for these receptors include alpha-MSH (α-MSH), beta-MSH, gamma-MSH, and ACTH — all derived from a precursor protein called POMC (proopiomelanocortin), which is processed in the pituitary and hypothalamus.

MC4R and Sexual Function

MC4R is the receptor most directly implicated in PT-141's sexual effects. It is densely expressed in the paraventricular nucleus of the hypothalamus, an area centrally involved in reproductive behavior and autonomic control of erection and arousal.

When MC4R is activated in this region, it triggers a cascade that includes the release of oxytocin (involved in bonding and arousal) and activation of pro-erectile pathways in the spinal cord. The result is not merely increased blood flow to genitals — it is a neurologically generated state of desire and arousal that precedes and drives the physical response.

This distinction matters. MC4R agonism produces desire. PDE5 inhibitors produce capacity. Both are relevant to sexual function, but they address different dimensions of the problem.

How PT-141 Works: Brain-Based vs Vascular

The standard model of pharmaceutical sexual dysfunction treatment for the past three decades has been vascular: identify a peripheral bottleneck in the physiological process (insufficient vasodilation, typically) and remove it pharmacologically. Sildenafil (Viagra) inhibits PDE5, preventing the breakdown of cGMP, which relaxes smooth muscle in penile and vaginal tissue and increases blood flow. It works downstream — on the physical execution of sexual response, not on the desire that initiates it.

PT-141's mechanism runs upstream of this entire process.

After subcutaneous injection, bremelanotide enters the bloodstream and crosses the blood-brain barrier (its cyclic structure aids this transit). Once in the CNS, it activates MC3R and MC4R receptors in the hypothalamic regions that govern sexual motivation. The hypothalamic response involves:

• Release of oxytocin from the paraventricular nucleus — a neuropeptide associated with bonding, trust, and sexual arousal
• Activation of dopaminergic pathways in the mesolimbic system — the brain's reward and motivation circuitry
• Descending signals to the lumbosacral spinal cord, where the pro-erectile reflex arc originates, triggering both physical arousal and genital engorgement

The subjective experience that users report — increased desire, heightened sensitivity, emotional engagement in the sexual encounter — maps onto this neurological mechanism. It is not simply "I can get an erection more easily." It is, as trial participants frequently described it, "I actually wanted to."

This is clinically significant because for a large portion of people with sexual dysfunction — including the premenopausal women for whom Vyleesi is approved — the primary problem is not physical capacity but desire. The vascular treatment model was never well-suited to this population. The central melanocortin model is.

The Clinical Trials: What Phase III Actually Showed

The FDA approval of Vyleesi was based primarily on two Phase III randomized controlled trials known collectively as the RECONNECT studies, published in 2016 and expanded through 2019 data submissions.

RECONNECT Study 1 and Study 2

Both RECONNECT trials enrolled premenopausal women (18–50 years) with a diagnosis of acquired, generalized HSDD — defined as low sexual desire causing marked distress, not explained by another medical condition, relationship factor, or other sexual dysfunction.

Key parameters:

• RECONNECT Study 1: N = 394 women. Randomized 1:1 to bremelanotide 1.75 mg subcutaneous or placebo, administered as needed before anticipated sexual activity over a 24-week period.
• RECONNECT Study 2: N = 440 women. Same design, independent trial for regulatory confirmation.

The primary outcomes measured were:

1. Change from baseline in the Female Sexual Function Index desire domain score (a validated patient-reported outcomes tool)
2. Change in the Female Sexual Distress Scale – Desire/Arousal/Orgasm (FSDS-DAO) item 13 score, which measures distress associated with low sexual desire

What the Data Showed

Both primary endpoints were met with statistical significance in both studies. Women taking bremelanotide showed significantly greater improvements in desire scores and significantly greater reductions in distress related to low desire compared to placebo.

The effect sizes were modest but clinically meaningful — a pattern consistent with other sexual dysfunction treatments. The proportion of women who responded to bremelanotide versus placebo was the more practically useful signal:

• Approximately 25% of bremelanotide users reported a meaningful improvement in sexual desire (defined as ≥1.2-point improvement on the FSFI desire subscale)
• Versus approximately 17% of placebo users — a placebo response rate that is itself significant and characteristic of sexual outcomes trials

Satisfaction with overall sexual experience also improved in the treatment group. The number needed to treat (NNT) was approximately 12 — meaning roughly one in every twelve women treated derived a meaningful benefit beyond what they would have gotten from placebo. This is comparable to or better than NNT estimates for flibanserin (Addyi), the other approved HSDD treatment.

What the Trials Did Not Show

The RECONNECT trials enrolled only premenopausal women with HSDD. The trials did not include:

• Postmenopausal women
• Men (any indication)
• People with situational or partner-specific sexual dysfunction
• People whose primary dysfunction is orgasm or arousal rather than desire

These are populations in which PT-141 is used off-label, based on mechanistic plausibility and earlier Phase II data — but Phase III-level evidence is absent for these groups.

FDA Approval: Vyleesi and What It Covers

The FDA approved bremelanotide (Vyleesi) on June 21, 2019 — the same day as a separate approval for an unrelated drug, which meant the announcement received less coverage than it warranted for a first-in-class mechanism. Vyleesi is available only by prescription in the United States.

Approved Indication

The approved indication is narrow:

• Premenopausal adult women
• With acquired, generalized hypoactive sexual desire disorder (HSDD)
• HSDD defined as: low sexual desire not explained by a coexisting medical or psychiatric condition, effects of a medication or substance, relationship problems, or other sexual dysfunction
• "Acquired" means the dysfunction was not lifelong — it developed after a period of normal desire
• "Generalized" means the dysfunction occurs in all situations, not only with certain partners or in certain contexts

Dosing and Administration

Vyleesi comes as a prefilled autoinjector pen containing 1.75 mg of bremelanotide in 0.4 mL. The injection is administered subcutaneously in the abdomen or thigh, 45 minutes before anticipated sexual activity.

FDA-labeled restrictions:

• Maximum one dose per 24-hour period
• Maximum eight doses per month
• Do not use with alcohol (increases nausea risk significantly)
• Do not administer intravenously

Why Not Postmenopausal Women?

The FDA approved Vyleesi only for premenopausal women because the clinical trials enrolled only that population. The hormonal environment changes significantly at menopause — estrogen decline affects vaginal tissue, lubrication, and the central systems involved in desire — and the regulatory position is that effectiveness in premenopausal women cannot be extrapolated to postmenopausal women without supporting trial data.

This is a regulatory statement about evidence, not a pharmacological one. PT-141's mechanism is not estrogen-dependent. Postmenopausal use is not prohibited — it is simply off-label, without the evidentiary support that carries an FDA approval.

Off-Label Use in Men

PT-141 has a longer history in men than Vyleesi's labeling suggests. Early Phase I and II trials of bremelanotide actually included male subjects with erectile dysfunction — and the results were interesting enough that the research continued before the program was redirected toward HSDD in women.

Early Male Data

In a 2004 Phase II trial published in the International Journal of Impotence Research, bremelanotide administered intranasally to men with erectile dysfunction produced statistically significant improvements in erectile function scores (IIEF scores) compared to placebo. Crucially, this included men who did not respond adequately to sildenafil (Viagra) — suggesting that the melanocortin pathway offers something distinct from and potentially complementary to PDE5 inhibition.

The early trial was halted not for efficacy reasons but because of the blood pressure elevation — intranasal delivery was delivering inconsistent doses and the hypertensive response was difficult to manage. Reformulation to subcutaneous delivery (which allows more predictable dosing and pharmacokinetics) addressed this.

Current Off-Label Use

Today, PT-141 is used off-label in men primarily for:

• Low libido — desire-side erectile dysfunction where the primary issue is motivation rather than physical capacity
• Psychogenic erectile dysfunction — where performance anxiety and psychological factors dominate over vascular dysfunction
• Non-response to PDE5 inhibitors — when Viagra and Cialis don't produce adequate results, the central mechanism of PT-141 addresses a different target
• Adjunct to TRT or peptide protocols — some men use PT-141 situationally alongside testosterone therapy

Off-label use in men is not FDA-sanctioned and lacks Phase III evidence. Compounded bremelanotide is available by prescription for this purpose at physician discretion. The clinical pharmacology is mechanistically sound, but men considering PT-141 should do so under medical supervision.

PT-141 vs PDE5 Inhibitors (Viagra, Cialis)

The most common question about PT-141 is how it compares to the established pharmacological standard in sexual dysfunction: PDE5 inhibitors like sildenafil (Viagra) and tadalafil (Cialis). The honest answer is that they are not directly comparable — they address fundamentally different aspects of the problem.

When PDE5 Inhibitors Work Better

PDE5 inhibitors are the first-line treatment for male erectile dysfunction caused by vascular insufficiency — which represents the majority of organic erectile dysfunction cases. They are oral, well-tolerated in most users, widely available as generics, and have decades of safety data. For the man whose primary problem is "I can't maintain an erection once I'm aroused," a PDE5 inhibitor is the pharmacologically appropriate tool.

When PT-141 May Work Better (or Differently)

• When the primary dysfunction is desire-based — the problem is wanting to have sex, not the physical response
• When PDE5 inhibitors have failed or produced inadequate results
• For women, for whom PDE5 inhibitors have not demonstrated consistent benefit and are not approved
• When the context includes significant psychological components — PT-141's CNS mechanism may address the motivational dimension that Viagra cannot

Can They Be Combined?

PT-141 and PDE5 inhibitors have different mechanisms, different receptor targets, and different physiological effects. Their pharmacological interaction is not well-characterized in formal trials, but they are not inherently contraindicated together. Many users and prescribers use them in combination. The caveat is that combining two compounds that affect cardiovascular function (one raising BP, one lowering it) warrants medical oversight, not self-administration.

Side Effects: What to Expect

PT-141's side effect profile is one of the most important factors in managing expectations — and in distinguishing appropriate use from inappropriate self-experimentation.

Nausea — The Primary Concern

Nausea is the most common and clinically significant side effect of PT-141. In the RECONNECT Phase III trials, approximately 40% of bremelanotide users reported nausea, compared to 1% of placebo users. This is a meaningful rate — high enough that the prescribing label warns about it explicitly and recommends assessment of nausea history before starting treatment.

The nausea is generally:

• Onset: 30–60 minutes after injection (coincides with peak plasma levels)
• Duration: Typically 1–3 hours, resolves without treatment in most cases
• Severity: Mild to moderate in most users; severe in a small minority
• Predictability: Tends to be consistent for a given individual — if you tolerate the first dose, subsequent doses are likely similar

Mitigation strategies used clinically include starting at lower doses (0.5–1 mg rather than the full 1.75 mg), pre-dosing with antiemetics (8 mg oral ondansetron is commonly used), and administering the injection in the thigh rather than abdomen. Alcohol significantly worsens nausea and should be avoided around the time of use.

Flushing and Injection Site Effects

Flushing — a warm, reddening sensation in the face and chest — affects approximately 20% of users. It is transient and generally not medically significant, but it can be noticeable and unwanted in the context of sexual activity. Injection site reactions including bruising, redness, and localized discomfort are common with any subcutaneous injection and are generally mild.

Blood Pressure Elevation

The transient blood pressure increase (average +6 mmHg systolic) is pharmacologically predictable given PT-141's MC4R activity in autonomic regulatory centers. In healthy individuals with normal baseline blood pressure, this elevation is not clinically significant. In individuals with hypertension, cardiovascular disease, or other conditions that make blood pressure increases dangerous, this side effect is the reason for the cardiovascular contraindication.

Hyperpigmentation

With frequent or prolonged use, PT-141 can cause localized darkening of the skin — particularly affecting the face, gums, and breasts. This is an expected consequence of its activity at MC1R receptors (the melanin-production receptor), which are also activated to some degree by bremelanotide despite its preference for MC3R/MC4R.

Hyperpigmentation is more likely with use exceeding the FDA-recommended 8 doses per month limit. It may be partially reversible on discontinuation but can persist. The FDA labeling includes a warning about this effect.

Vyleesi vs Compounded PT-141

There are two ways to access bremelanotide in the United States: through the FDA-approved commercial product (Vyleesi) or through a compounding pharmacy by prescription.

Vyleesi (FDA-Approved)

Vyleesi is manufactured by AMAG Pharmaceuticals (later acquired), available by prescription from any licensed prescriber. It comes as a single-use, prefilled autoinjector at the FDA-approved 1.75 mg dose.

The practical limitations of Vyleesi:

• Cost: Expensive without insurance. List price has been in the range of $800–$1,000 per box (4 injectors). Insurance coverage varies significantly.
• Fixed dose: The autoinjector delivers exactly 1.75 mg — there is no option to start at a lower dose to assess tolerability, which makes the nausea side effect harder to manage
• Indication scope: Labeled only for premenopausal women with HSDD — prescribers may hesitate to prescribe off-label for men or postmenopausal women

Compounded Bremelanotide

Compounding pharmacies can prepare bremelanotide as a lyophilized powder or solution for subcutaneous injection at doses that can be customized. This allows:

• Starting doses as low as 0.5 mg to assess tolerability
• Titration to the effective dose for that individual
• Intranasal formulations (for those who prefer to avoid injections, though bioavailability is lower and less predictable)
• Access for men and other populations via off-label prescription
• Significantly lower cost than Vyleesi

The critical caveat: compounded products are not FDA-approved. They are not evaluated for potency, purity, or sterility by the FDA as a condition of market entry. Compounded bremelanotide from a reputable, PCAB-accredited or 503B-registered compounding pharmacy is generally reliable — but the quality control environment is different from a pharmaceutical manufacturing facility. Source matters.

Bottom Line: Honest Evidence Assessment

PT-141 occupies a genuine and largely unoccupied niche in the pharmacology of sexual function: a centrally acting, brain-based approach to desire and arousal with FDA-approved Phase III evidence behind it.

What the evidence supports:

• Statistically and clinically significant improvement in sexual desire in premenopausal women with HSDD — two Phase III RCTs confirm this
• A mechanism that addresses the desire component of sexual dysfunction rather than the physical response component — relevant for populations underserved by PDE5 inhibitors
• A manageable but real side effect profile, dominated by nausea, that requires appropriate starting doses and expectation-setting
• Early Phase II evidence of efficacy in men, particularly those who don't respond to PDE5 inhibitors — plausible but not at Phase III standard

What the evidence does not yet support:

• Phase III-level efficacy in men (no large RCT)
• Efficacy in postmenopausal women (different hormonal context; no Phase III data)
• Long-term safety beyond the trial duration (the hyperpigmentation risk may compound with chronic use)
• Use without medical supervision — the cardiovascular contraindication is real, and the blood pressure effect requires assessment

Frequently Asked Questions